Biogen to Acquire Apellis for $41.00 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy BIIB?
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 187.570
Low
143.00
Averages
204.45
High
246.00
Current: 187.570
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Deal: Biogen announced on Tuesday its acquisition of Apellis Pharmaceuticals for $5.6 billion, significantly enhancing its drug pipeline by adding two approved drugs, thereby solidifying its market position in the biopharmaceutical sector.
- Pipeline Expansion: This acquisition will introduce two approved drugs into Biogen's product portfolio, which is expected to provide robust support for the company's future revenue growth, particularly in applications within the neuroscience field.
- Strategic Market Shift: By acquiring Apellis, Biogen not only boosts its competitiveness in the biopharmaceutical market but also aims to optimize R&D efficiency through the integration of Apellis's technologies and resources, fostering the development of innovative drugs.
- Financial Impact: The transaction is expected to positively affect Biogen's financial status; although the acquisition cost is substantial at $5.6 billion, the anticipated market sales from the new drugs are expected to yield significant returns on investment.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Deal: Biogen announced on Tuesday its acquisition of Apellis Pharmaceuticals for $5.6 billion, significantly enhancing its drug pipeline by adding two approved drugs, thereby solidifying its market position in the biopharmaceutical sector.
- Pipeline Expansion: This acquisition will introduce two approved drugs into Biogen's product portfolio, which is expected to provide robust support for the company's future revenue growth, particularly in applications within the neuroscience field.
- Strategic Market Shift: By acquiring Apellis, Biogen not only boosts its competitiveness in the biopharmaceutical market but also aims to optimize R&D efficiency through the integration of Apellis's technologies and resources, fostering the development of innovative drugs.
- Financial Impact: The transaction is expected to positively affect Biogen's financial status; although the acquisition cost is substantial at $5.6 billion, the anticipated market sales from the new drugs are expected to yield significant returns on investment.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion
- Acquisition Details: Apellis Pharmaceuticals has agreed to be acquired by Biogen for $41 per share, totaling $5.6 billion, with the deal expected to close in Q2 2026, reflecting Biogen's strong interest and confidence in the market.
- Shareholder Value Enhancement: The transaction offers Apellis shareholders $41 in cash per share, representing an 86% premium over its 90-day volume-weighted average stock price, while also providing a nontransferable contingent value right worth $2 per share tied to Syfovre's net sales, further enhancing investment appeal.
- Product Portfolio Expansion: The acquisition will add Apellis' Empaveli and Syfovre to Biogen's portfolio, which generated $689 million in revenue last year, expected to strengthen Biogen's competitive position in the ophthalmic drug market.
- Financial Outlook Improvement: Biogen plans to fund the acquisition through a mix of cash and debt, anticipating an increase in its non-GAAP diluted EPS in 2027 and a compounded annual growth rate through 2030, indicating a positive impact on its long-term financial health.
See More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion
- Acquisition Announcement: Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, resulting in a 140% surge in Apellis' shares during Tuesday's pre-market trading, indicating strong market enthusiasm and a significant boost to Biogen's position in the rare disease treatment sector.
- Retail Sentiment: Following the acquisition news, retail sentiment around Apellis on Stocktwits trended bullish with high message volumes, reflecting investor optimism about the company's future prospects, which could further drive up its stock price.
- Business Expansion: This acquisition will enhance Biogen's rare disease treatment portfolio and accelerate its expansion into nephrology, signaling a strategic shift towards high-growth areas to capture increasing market demand.
- Investor Attention: As the acquisition progresses, market focus on Apellis has intensified, with investors likely to closely monitor the integration process and its impact on Biogen's overall performance, suggesting potential future stock price volatility.
See More
